ProtoPulse · CNAS therapeutic protocols
Data updated 19 Oct 2026, 22:37 · printed from ProtoPulse

AMIVANTAMABUM

Active substance (INN) · ATC L01FX18 · 5 products authorised in Romania
◀ Back
1

Protocols it appears in

As a medicine of the protocol (in the title) or only mentioned in the text

CodeProtocolStatusRoleSublistGP
L01FX18 AMIVANTAMABUM In force medicine of the protocol C2-P3 NO
2

Authorised brand products (ANMDM)

The Romanian register of medicines for human use, updated daily

Brand nameFormStrengthHolderATCRx
RYBREVANT 1600 mgSOL INJ.1600mgJANSSEN-CILAG INTERNATIONAL NV - BELGIAL01FX18PR
RYBREVANT 2240 mgSOL INJ.2240mgJANSSEN-CILAG INTERNATIONAL NV - BELGIAL01FX18PR
RYBREVANT 2400 mgSOL INJ.2400mgJANSSEN-CILAG INTERNATIONAL NV - BELGIAL01FX18PR
RYBREVANT 350 mgCONC. PT. SOL. PERF.350mgJANSSEN-CILAG INTERNATIONAL NV - BELGIAL01FX18PR
RYBREVANT 3520 mgSOL INJ.3520mgJANSSEN-CILAG INTERNATIONAL NV - BELGIAL01FX18PR

Data extracted automatically from the documents published by CNAS (cnas.ro/protocoale-terapeutice) and from the ANMDM medicines register. For information only; the official text (the Ministry of Health / CNAS orders published in the Official Gazette) prevails. Protocol names and texts are shown in Romanian, as published.